|
|
Yoshiaki Tsutsumi, Hiroaki Matsubara, Hiroya Masaki, Hiroki Kurihara, Satoshi Murasawa, Shinji Takai, Mizuo Miyazaki, Yoshihisa Nozawa, Ryoji Ozono, Keigo Nakagawa, Takeshi Miwa, Noritaka Kawada, Yasukiyo Mori, Yasunobu Shibasaki, Yohko Tanaka, Soichiro Fujiyama, Yohko Koyama, Atsuko Fujiyama, Hakuo Takahashi, Toshiji Iwasaka
J Clin Invest. 1999;
104(7):925
doi:10.1172/JCI7886
Abstract |
Full text
| PDF

A
ngiotensin II (Ang II) is a potent vasopressor peptide that interacts with 2 major receptor isoforms — AT1 and AT2. Although blood pressure is increased in AT2 knockout mice, the underlying mechanisms remain undefined because of the low levels of expression of AT2 in the vasculature. Here we overexpressed AT2 in vascular smooth muscle (VSM) cells in transgenic (TG) mice. Aortic AT1 was not affected by overexpression of AT2. Chronic infusion of Ang II into AT2-TG mice completely abolished the AT1-mediated pressor effect, which was blocked by inhibitors of bradykinin type 2 receptor (icatibant) and nitric oxide (NO) synthase (L-NAME). Aortic explants from TG mice showed greatly increased cGMP production and diminished Ang II–induced vascular constriction. Removal of endothelium or treatment with icatibant and L-NAME abolished these AT2-mediated effects. AT2 blocked the amiloride-sensitive Na+/H+ exchanger, promoting intracellular acidosis in VSM cells and activating kininogenases. The resulting enhancement of aortic kinin formation in TG mice was not affected by removal of endothelium. Our results suggest that AT2 in aortic VSM cells stimulates the production of bradykinin, which stimulates the NO/cGMP system in a paracrine manner to promote vasodilation. Selective stimulation of AT2 in the presence of AT1 antagonists is predicted to have a beneficial clinical effect in controlling blood pressure.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(131)
| Title and authors |
Publication |
Year |
Insulin resistance induces a segmental difference in thoracic and abdominal aorta : differential expression of AT1 and AT2 receptors
Pinakin Arun Karpe, Jeena Gupta, Rickey F. Marthong, Poduri Ramarao, Kulbhushan Tikoo
|
Journal of Hypertension
|
2012 |
Hemodynamic effects of vasorelaxant compounds in mice lacking one, two or all three angiotensin II receptors
Florian Gembardt, Richard van Veghel, Thomas M Coffman, Heinz-Peter Schultheiss, Alexander H Jan Danser, Thomas Walther
|
Hypertens Res
|
2012 |
AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats
Quaisar Ali, Tahir Hussain
|
Hypertens Res
|
2012 |
The kallikrein–kinin system in diabetic nephropathy
Hirofumi Tomita, Ryan B Sanford, Oliver Smithies, Masao Kakoki
|
Kidney Int
|
2012 |
Angiotensin II type 2 receptor agonists: where should they be applied?
Koen Verdonk, A H Jan Danser, Joep H M van Esch
|
Expert Opin. Investig. Drugs
|
2012 |
Ontogeny of angiotensin-converting enzyme 2
Renfang Song, Graeme Preston, Ihor V. Yosypiv
|
Paediatric Research
|
2012 |
Branched-chain amino acid supplemented diet during maternal food restriction prevents developmental hypertension in adult rat offspring
T. Fujii, S. Yura, K. Tatsumi, E. Kondoh, H. Mogami, K. Fujita, K. Kakui, S. Aoe, H. Itoh, N. Sagawa, S. Fujii, I. Konishi
|
J Devel Orig Health Dis
|
2011 |
Comprehensive Physiology
Nour-Eddine Rhaleb, Xiao-Ping Yang, Oscar A. Carretero
|
Comprehensive Physiology
|
2011 |
Angiotensin type 2 receptor in hypertensive cardiovascular disease
Carmine Savoia, Michela DʼAgostino, Francesco Lauri, Massimo Volpe
|
Current Opinion in Nephrology and Hypertension
|
2011 |
Non-peptide AT2-receptor agonists
U Muscha Steckelings, Mats Larhed, Anders Hallberg, Robert E Widdop, Emma S Jones, Charlotta Wallinder, Pawel Namsolleck, Björn Dahlöf, Thomas Unger
|
Current Opinion in Pharmacology
|
2011 |
|